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SUMMARY
The relationship between exocrine pancreatic function and plasma pancreatic
polypeptide levels was studied in 14 normal elderly subjects and in ten elderly
patients with exocrine pancreatic insufficiency determined by the para-amino-
benzoic acid test. There was a decrease in the total pancreatic polypeptide
response after a standard mixed meal in the group with pancreatic insufficiency
(t =2- 753, p = 0*01). An increase above basal of less than 100% in plasma
pancreatic polypeptide levels 30 min after a standard mLxed meal is strongly
associated with exocrinepancreatic insufficiency(Fisher's exact test, p = 0*005).
INTRODUCTION
The para -aminobenzoic acid test is a standard non -invasive test for exocrine
pancreatic insufficiency. Its high sensitivity and specificity in identifying cases of
severe exocrine pancreatic insufficiency merit its use asascreening tool, although
it is less accurate for moderate cases.1 Elderly people have difficulty coping
with this test, and a simpler, equally reliable, initial screening test for exocrine
pancreatic insufficiency would be welcome.
Plasmalevelsofpancreatic polypeptidearerelated toexocrine pancreatic function
in both normal and diseased states.2-4 Pancreatic polypeptide, a 36 amino acid
peptide, inhibits exocrine pancreatic secretion.5 In healthy adults (aged 18-46
years) plasma pancreatic polypeptide levels following nutrient and hormonal
stimulation are closely related to exocrine pancreatic function.4 Stimulated levels
of pancreatic polypeptide are reduced in exocrine pancreatic insufficiency.3 This
suggests that plasma pancreatic polypeptide measurement may be a useful
screening test for exocrine pancreatic insufficiency.6 It is not known whether such
a relationship between pancreatic polypeptide secretion and exocrine pancreatic
function also exists in the elderly. If it did, plasma pancreatic polypeptide levels
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after a standard mixed meal could be used as a screening test before proceeding
to para -aminobenzoic acid or more invasive testing. The present study investig-
ated the relationship between the plasma pancreatic polypeptide response to a
standard mixed meal in elderly subjects with normal and abnormal para-amino-
benzoic acid (PABA) tests.
SUBJECTS AND METHODS
Fourteen elderly subjects (group 1), mean (± SE) age 74
-7 ± 1 -4 years with
normal para -aminobenzoic acid (PABA) tests, and five asymptomatic subjects
(group 2), with a para-aminobenzoic acid excretion index of less than 55% were
recruited from a previous study. In that study a sample of 21 healthy subjects,
over the age of 65 years and living independently in the community, were
screened for evidence of pancreatic insufficiency by para-aminobenzoic acid
testing. Those with significant hepatic or renal disease or a history of gastro-
intestinal surgery, alcohol excess or diabetes mellitus were excluded from the
study.7 Five additional subjects, aged over 60 years, with moderate to severe
exocrine pancreatic insufficiency (para-aminobenzoic acid excretion index less
than 55% and symptoms/signs of malabsorption) diagnosed in the previous 12
months and studied pre-treatment were also included in group 2. The mean age
of the ten patients in group 2 was 68-5 ± 1 -5 years.
The modified para-aminobenzoic acid test8 consists of two stages. On day 1,
after overnight fasting, N -benzoyl-1-tryosyl -para -aminobenzoic acid is given
along with a standard mixed meal of 50 g of carbohydrate, 18 g of protein and
20 g of fat and the urine is collected over the next 6 hours. N -benzoyl-1 -tryosl-
para
-aminobenzoic acid requires pancreatic chymotrypsin to liberate para -
aminobenzoic acid which is then absorbed and excreted in the urine. On day 2
the procedure is repeated with para -aminobenzoic acid to exclude causes of
malabsorption otherthan pancreatic insufficiency. The para -aminobenzoic acid
excretion index is then calculated as the percentage of day 1/day 2 urinary para -
aminobenzoic acid excretion, a figure of less than 55% indicating exocrine
pancreatic insufficiency. To ensure that all urine was collected, a named nurse
accompanied each patient throughout each 6 hour period, a single toilet was set
apart for each subject and urine was collected using a urinal. Blood samples for
insulin and pancreatic polypeptide levels were taken at -15, 0, 15, 30, 60, 90
and 120 min following ingestion of a standard mixed meal. The samples were
centrifugedand plasma was stored at - 20ICuntil thestudy had been completed.
The hormones were measured by radioimmunoassay.9
Statistical analysis: The unpaired t-test was used to compare the area under the
curve and individual results for the log transformation of pancreatic polypeptide
and insulin responses over the first hour (which covers the initial rise in plasma
pancreatic polypeptide) after a standard mixed meal between groups 1 and 2.
(The log transformation was applied to the data as the response for pancreatic
polypeptide and insulin over time was skewed). Fisher's exact test was used
to examine the association between para -aminobenzoic acid testing and the
percentage rise in plasma pancreatic polypeptide levels at 30 minutes after a
standard mixed meal compared with basal (-15 min) plasma pancreatic poly-
peptide levels (a riseof less than 100% was taken asindicating abnormal exocrine
pancreatic function).
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Fig 1. Log transformation, with 95% confidence limits, of plasma pancreatic polypeptide (PP) and
insulin responses to a standard mixed meal (SMM) in elderly subjects with normal (group 1) and
abnormal (group 2) responses to the para aminobenzoic acid (PABA) test for exocrine pancreatic
insufficiency.
RESULTS
All subjects had a serum creatinine of <131 umol/1. Urinevolumes (mean ±SE) in
group 1 on day 1 and day 2 ofthe para -aminobenzoic acid test were 794 ± 102 ml
and 1233 ± 144 ml and in group 2, 708 ±77 ml and 988 ± 106 ml, respectively.
Basal (15 minutes prior to a standard mixed meal) and stimulated (15 to 60
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minutes after a standard mixed meal) plasma pancreatic polypeptide and insulin
levels were compared between groups 1 and 2 (Fig 1). The basal pancreatic
polypeptidelevels(mean SE)were 99 9 18*5 pg/mland 69*5 17- pg/ml,
respectively. The total area under the curve for log pancreatic polypeptide and
log insulin responses over time was significantly less in group 2 (pancreatic
polypeptide p = 0-01, insulin p=0
-007). The log pancreatic polypeptide and
log insulin levels in group 2 at 15, 30, and 60 min after the standard mixed
meal were also significantly less compared with group 1.
Ifthe 30 minute plasma pancreatic polypeptide level was less than 100% greater
than fasting, the patient very probably had an abnormal para -aminobenzoic acid
test (Fisher's exact test p= 0 005). (Fig 2).
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Fig 2. Rise in plasma pancreatic polypeptide (PP) from 15 minutes before to 30 minutes after a
standard mixed meal in groupl (normal) and group 2 (abnormal PABA test). p=0 = 005, Fisher's
exact test.
DISCUSSION
Within a few minutes of ingesting food there is a rapid initial rise in plasma
pancreatic polypeptide, which tails off after 30 -60 minutes. This is followed by
a secondary rise lasting for several hours.10 The initial rise, closely related to
exocrine pancreatic secretion, is due to vagal stimulation,1" the secondary rise
maybeneurohormonal.12 In man, pancreatic polypeptide storage cellsarelocated
mainly in the head and uncinate process of the pancreas. They are widely
distributed between the exocrine acinar and the endocrine islet cells.13 Function-
ally, both pancreatic polypeptide and exocrine pancreatic enzyme secretion
require an intact vagal pathway.1M 14 They can be stimulated by ingestion of food
or the intravenous injection of secretin/cholecystokinin.6 15. 16
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In animal models of exocrine pancreatic insufficiency the reduction in exocrine
pancreatic secretion in response to food is associated with a decline in pancreatic
polypeptide response in the first 60 minutes and a normal secondary rise due to
an intact endocrine axis.17 In patients with moderate tosevere exocrine pancreatic
insufficiency reduced pancreatic enzyme outputis associated with lowbasal levels
ofplasma pancreatic polypeptide and a flat or attenuated rise following astandard
mixed meal or cholecystokinin infusion2 3 related to the degree of exocrine
pancreatic insufficiency.4 In normal elderly subjects basal levels of plasma
pancreatic polypeptide are elevated.18 The cause and the significance of this
elevation are unclear.
In the present study the basal plasma pancreatic polypeptide levels in group 1
and group 2 subjects were within the normal range (0-200 pg/ml). There was
no significant difference in basal plasma pancreatic polypeptide levels between
the two groups. In both groups there was an initial rise in plasma pancreatic
polypeptide levels in response to a standard mixed meal, but the magnitude
of this response over time was significantly diminished in those with exocrine
pancreatic insufficiency. This may in part be due to a decrease in pancreatic
exocrine secretions in the duodenum or a decrease in the number or the function
of pancreatic polypeptide producing cells.4 Along with the flattened pancreatic
polypeptide response in these patients there was a lower plasma insulin response,
indicating concomitant beta cell damage or malfunction.
Thisreduced pancreatic polypeptide responseintheelderlysubjects withexocrine
pancreatic insufficiency agrees with studies in younger subjects.2-4 In this study,
a strong association was found between a rise in plasma pancreatic polypeptide
levels at 30 min of less than 100% and the presence of exocrine pancreatic
insufficiency as determined by para -aminobenzoic acid testing, which may prove
to be a simpler screening test for exocrine pancreatic insufficiency in the elderly.
Para -aminobenzoic acid testing cannot beused toquantify the degreeofexocrine
pancreatic insufficiency, but it does help to differentiate patients with moderate
to severe pancreatic insufficiency from those with normal exocrine pancreatic
function or only mild impairment." 19 A similar limitation may also apply to
pancreatic polypeptide measurement for assessing exocrine pancreatic function.4
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